Table 1.
Clinical characteristics.
| Clinical Characteristics | Cohort (N = 117) |
|
|---|---|---|
| Age at surgery (years) | ||
| N | 117 (100%) | |
| Mean (SD) | 66.4 (8.2) | |
| Range | 41–82 | |
| Center | ||
| France: La Louvière (Lille) | 9 (7.7%) | |
| France: HEGP (Paris) | 20 (17.1%) | |
| France: IMM (Paris) | 49 (41.9%) | |
| France: Diaconnesses and St Jean de Dieu (Paris) | 27 (23.1%) | |
| Greece: Alexandra | 12 (10.3%) | |
| Gender | ||
| Male | 91 (77.8%) | |
| Female | 26 (22.2%) | |
| Professional toxic exposure | ||
| No | 75 (64.1%) | |
| Yes | 10 (8.5%) | |
| Not available | 32 (27.4%) | |
| Tobacco use | ||
| No | 27 (23.1%) | |
| Yes | 78 (66.7%) | |
| Not available | 12 (10.3%) | |
| Previous cancer with chemotherapy or pelvic radiotherapy | ||
| No | 106 (90.6%) | |
| Yes | 6 (5.1%) | |
| Not available | 5 (4.3%) | |
| Site of primary tumor | ||
| Bladder | 115 (98.3%) | |
| Bladder + upper tract | 1 (0.9%) | |
| Upper tract | 1 (0.9%) | |
| Histologic variant | ||
| Urothelial carcinoma | 99 (84.6%) | |
| Variant | 17 (14.5%) | |
| Not Available | 1 (0.9%) | |
| T stage | ||
| T2 | 106 (90.6%) | |
| T3–4 | 7 (6%) | |
| Not available | 4 (3.4%) | |
| N stage | ||
| N0 | 31 (26.5%) | |
| N+ | 77 (65.8%) | |
| Not Available | 9 (7.7%) | |
| Prior BCG therapy | ||
| No | 93 (79.5%) | |
| Yes | 24 (20.5%) | |
| Creatinine clearance (MDRD) | ||
| n | 44 (37.6%) | |
| Mean (SD) | 81.8 (20.2) | |
| Range | 49–150 | |
| Not Available | 73 (62.4%) | |
| Neoadjuvant chemotherapy type | ||
| MVAC | 66 (56.4%) | |
| GC | 44 (37.6%) | |
| Carboplatin based | 3 (2.5%) | |
| Other platinum-based | 4 (3.4%) | |
| pCR | ||
| No | 66 (56.4%) | |
| Yes | 35 (29.9%) | |
| Not Available | 16 (13.7%) | |
HEGP: Hôpital Européen Georges Pompidou, IMM: Institut Mutualiste Montsouris, BCG: Bacille Calmette et Guérin, MDRD: Modification of Diet in Renal Diseases, MVAC: Methotrexate, Vinblastine, Adriamycine, and Cisplatin; GC: Gemcitabine and Cisplatin; pCR: pathologic complete response.